Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Gynecol Oncol Rep ; 37: 100855, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34541275

ABSTRACT

OBJECTIVE: Tumors harboring a POLE pathogenic variant, associated with high tumor mutational burden, are good candidates for immunotherapy. However, POLE pathogenic variants are not currently screened in routine clinical practice. Can these tumors be identified by means of an already available test? METHODS: We describe seven tumors harboring a POLE pathogenic variant, among eight patients with tumors harboring multiple BRCA1/2 variants (from 4 to 20). All patients were managed at Institut Curie, Paris. Five patients were selected because of unexpected tumor BRCA testing results with multiple variants and another three patients were selected because of a POLE pathogenic variant detected by large tumor testing. We looked for other tumor variants by Next-Generation Sequencing in tumors harboring multiple BRCA1/2 variants, and for multiple BRCA1/2 variants in tumors harboring a POLE pathogenic variant. RESULTS: Four of the five tumors selected because of multiple BRCA1/2 variants exhibited a POLE pathogenic variant, and all three tumors selected for POLE pathogenic variants exhibited multiple BRCA1/2 variants. CONCLUSIONS: Tumor BRCA testing could be a way to detect tumors harboring a highly mutagenic POLE pathogenic variant.

2.
ESMO Open ; 6(3): 100154, 2021 06.
Article in English | MEDLINE | ID: mdl-34022731

ABSTRACT

BACKGROUND: Chemoradiotherapy (CRT) is the standard of care for patients diagnosed with locally advanced cervical cancer (LACC), a human papillomavirus (HPV)-related cancer that relapses in 30%-60% of patients. This study aimed to (i) design HPV droplet digital PCR (ddPCR) assays for blood detection (including rare genotypes) and (ii) monitor blood HPV circulating tumor DNA (HPV ctDNA) levels during CRT in patients with LACC. METHODS: We analyzed blood and tumor samples from 55 patients with HPV-positive LACC treated by CRT in a retrospective cohort (n = 41) and a prospective cohort (n = 14). HPV-ctDNA detection was carried out by genotype-specific ddPCR. RESULTS: HPV ctDNA was successfully detected in 69% of patients (n = 38/55) before CRT for LACC, including nine patients with a rare genotype. HPV-ctDNA level was correlated with HPV copy number in the tumor (r = 0.41, P < 0.001). HPV-ctDNA positivity for HPV18 (20%, n = 2/10) was significantly lower than for HPV16 (77%, n = 27/35) or other types (90%, n = 9/10, P = 0.002). HPV-ctDNA detection (positive versus negative) before CRT was associated with tumor stage (P = 0.037) and lymph node status (P = 0.02). Taking into account all samples from the end of CRT and during follow-up in the prospective cohort, positive HPV-ctDNA detection was associated with lower disease-free survival (DFS) (P = 0.048) and overall survival (OS) (P = 0.0013). CONCLUSION: This is one of the largest studies to report HPV-ctDNA detection before CRT and showed clearance of HPV ctDNA at the end of treatment in most patients. Residual HPV ctDNA at the end of CRT or during follow-up could help to identify patients more likely to experience subsequent relapse.


Subject(s)
Alphapapillomavirus , Circulating Tumor DNA , Papillomavirus Infections , Uterine Cervical Neoplasms , Chemoradiotherapy , Circulating Tumor DNA/genetics , Female , Humans , Neoplasm Recurrence, Local , Papillomaviridae/genetics , Papillomavirus Infections/diagnosis , Papillomavirus Infections/therapy , Prospective Studies , Retrospective Studies , Uterine Cervical Neoplasms/therapy
3.
Ann Oncol ; 30(12): 1941-1949, 2019 12 01.
Article in English | MEDLINE | ID: mdl-31566659

ABSTRACT

BACKGROUND: Although stromal tumor-infiltrating lymphocytes (sTILs) have been considered an important prognostic factor in early-stage triple-negative breast cancer (TNBC), there have been limited data on their prognostic value in the absence of adjuvant chemotherapy. PATIENTS AND METHODS: A pooled analysis was carried out using four cohorts of TNBC patients not treated with chemotherapy. sTILs were evaluated in the most representative tumoral block of surgical specimens. Cox proportional hazards regression models were used for invasive disease-free survival (iDFS), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors. RESULTS: We analyzed individual data of 476 patients from 4 centers diagnosed between 1989 and 2015. Their median age was 64 years. The median tumor size was 1.6 cm and 83% were node-negative. The median level of sTILs was 10% (Q1-Q3, 4%-30%). Higher grade was associated with higher sTILs (P < 10-3). During follow-up, 107 deaths, and 173 and 118 events for iDFS and D-DFS were observed, respectively. In the multivariable analysis, sTILs obtained an independent prognostic value for all end points (likelihood ratio χ2 = 7.14 for iDFS; P < 10-2; χ2 = 9.63 for D-DFS, P < 10-2; χ2 = 5.96 for OS, P = 0.015). Each 10% increment in sTILs corresponded to a hazard ratio of 0.90 [95% confidence interval (CI) 0.82 - 0.97] for iDFS, 0.86 (95% CI 0.77 - 0.95) for D-DFS, and 0.88 (95% CI 0.79 - 0.98) for OS, respectively. In patients with pathological stage I tumors with sTILs ≥30% (n = 74), 5-year iDFS was 91% (95% CI 84% to 96%), D-DFS was 97% (95% CI 93% to 100%), and OS was 98% (95% CI 95% to 100%). CONCLUSION: sTILs add important prognostic information in systemically untreated early-stage TNBC patients. Notably, sTILs can identify a subset of stage I TNBC patients with an excellent prognosis without adjuvant chemotherapy.


Subject(s)
Biomarkers, Tumor/blood , Lymphocytes, Tumor-Infiltrating/metabolism , Triple Negative Breast Neoplasms/blood , Triple Negative Breast Neoplasms/drug therapy , Adult , Aged , Chemotherapy, Adjuvant/methods , Disease-Free Survival , Female , Humans , Lymphocytes, Tumor-Infiltrating/pathology , Middle Aged , Neoplasm Staging , Prognosis , Proportional Hazards Models , Triple Negative Breast Neoplasms/pathology
5.
Vet Res ; 27(2): 171-6, 1996.
Article in English | MEDLINE | ID: mdl-8721296

ABSTRACT

In a survey of coronavirus and rotavirus-induced neonatal diarrhoea in 373 calves from 284 farms, nine (2.4%) of the animals were found to be infected with non-group A rotaviruses when their faeces were analysed in a commercial ELISA and by PAGE. Seven out of eight 1-4- day-old kids from a single farm were also infected with similar viruses. In a mini-PAGE, all the viruses displayed group B- and/or E-like 4223 electrophoretypes. In Northern hybridizations with cDNA chemiluminescent probes specific to rotavirus groups A (RF strain), B (adult diarrhoea rotavirus, ADRV) and C (Cowden strain) all the viruses belonged to group B.


Subject(s)
Cattle Diseases , Diarrhea/veterinary , Goat Diseases , Rotavirus Infections/veterinary , Rotavirus/isolation & purification , Animals , Animals, Newborn , Base Sequence , Blotting, Northern , Cattle , DNA Primers , DNA Probes , DNA, Complementary , Diarrhea/virology , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , France , Goats , Luminescent Measurements , Molecular Sequence Data , Oligonucleotide Probes , Polymerase Chain Reaction/methods , Polymerase Chain Reaction/veterinary , RNA, Viral/analysis , Rotavirus/classification , Rotavirus/genetics , Rotavirus Infections/virology
6.
Int J Cancer ; 16(2): 255-65, 1975 Aug 15.
Article in English | MEDLINE | ID: mdl-1150353

ABSTRACT

MC57M and G are the tissue-culture derivatives of two methylcholanthrene-induced murine C57Bl sarcomas. Their sensitivity to immune cytoxic3, cytostatic or cytolytic spleen cells and sera was compared in parallel in vitro assays. The level of cross-reactivity displayed by the two lines was found to depend on the nature of the immune effector rather than on the assay which was used. It was high with immune spleen lymphocytes, alone or in the presence of decomplemented antisera, and low with antisera in the presence of rabbit complement. MC57G cells were more sensitive than MC57M cells to both effectors. Both cell lines were insensitive to antibody-dependent cell-mediated cytotoxicity. Preliminary evidence is presented, suggesting a probable involvement of embryonic and Moloney leukemia virus-induced cell surface antigens in the vitro sensitization of the two tumor lines to immune sera.


Subject(s)
Antigen-Antibody Reactions , Immunity, Cellular , Sarcoma, Experimental/immunology , Animals , Antigens, Neoplasm , Antigens, Viral , Cell Line , Cell Membrane/immunology , Complement System Proteins , Cross Reactions , Cytotoxicity Tests, Immunologic , Immune Sera , Lymphocytes/immunology , Methylcholanthrene , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Rabbits/immunology , Sarcoma, Experimental/chemically induced , Spleen/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...